ArriVent Targets PACC Mutation Market With EGFR TKI Firmonertinib In Lung Cancer

Drug Shows CNS Activity In Early Trial

 
• By Mandy Jackson
  
Lungs paper decorative model on light blue background
EGFR PACC mutations are more common in NSCLC than exon 20 insertion mutations • Source: Shutterstock

More from Clinical Trials

More from R&D